Cefdinir: Difference between revisions

(Created page with "==General== *Type: *Dosage Forms: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Pregnancy Rating: *Lac...")
 
No edit summary
 
(21 intermediate revisions by 9 users not shown)
Line 1: Line 1:
==General==
==General==
*Type:  
*Type: [[Is Generation::3rd generation]] [[Is DrugClass::cephalosporin]]
*Dosage Forms:
*Dosage Forms: capsule, oral suspension
*Common Trade Names:  
*Dosage Strengths: capsule: 300mg; oral suspension: 125mg/5mL, 250mg/5mL
*Routes of Administration: PO
*Common Trade Names: Omnicef


==Adult Dosing==
==Adult Dosing==
*600mg/d divided q12-24hrs for 10 days for [[CAP]], chronic [[bronchitis]], acute [[sinusitis]], [[strep pharyngitis]], [[cellulitis]]


==Pediatric Dosing==
==Pediatric Dosing==
*14mg/kg/d PO divided q12-24hrs x10 days, max of 600mg/day


==Special Populations==
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B
*Lactation:
*Lactation: Probably safe
*Renal Dosing
*Renal Dosing
**Adult
**Adult: CrCl <30, 300mg q24hrs; CrCl <10, 300mg q48hrs; supplement after HD
**Pediatric
**Pediatric: CrCl <30, 7mg/kg q24, max 300mg/dose; supplement after HD
*Hepatic Dosing
*Hepatic dosing not defined
**Adult
**Pediatric


==Contraindications==
==Contraindications==
Line 25: Line 27:


===Common===
===Common===
*Diarrhea
*Bloody stools which are guiac negative and returns to normal color after cessation<ref>Graves R, Weaver SP. Cefdinir-associated "bloody stools" in an infant. J Am Board Fam Med. 2008;21(3):246-248. doi:10.3122/jabfm.2008.03.070242</ref>


==Pharmacology==
==Pharmacology==
*Half-life:  
*Half-life: 100 min
*Metabolism:  
*Metabolism: Not appreciably metabolized
*Excretion:  
*Excretion: Urine (7-25% as unchanged drug)
*Mechanism of Action:
*Mechanism of Action: Bactericidal, inhibits bacterial cell wall synthesis
 
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==
{| class="wikitable"
| align="center" style="background:#f0f0f0;"|'''Group'''
| align="center" style="background:#f0f0f0;"|'''Organism'''
| align="center" style="background:#f0f0f0;"|'''Sensitivity'''
|-
| Gram Positive||[[Strep. Group A, B, C, G]]||'''S'''
|-
| ||[[Strep. Pneumoniae]]||'''S'''
|-
| ||[[Viridans strep]]||'''S'''
|-
| ||Strep. anginosus gp||X1
|-
| ||[[Enterococcus faecalis]]||R
|-
| ||[[Enterococcus faecium]]||X1
|-
| ||[[MSSA]]||'''S'''
|-
| ||[[MRSA]]||R
|-
| ||[[CA-MRSA]]||R
|-
| ||[[Staph. Epidermidis]]||I
|-
| ||[[C. jeikeium]]||X1
|-
| ||[[L. monocytogenes]]||R
|-
| Gram Negatives||[[N. gonorrhoeae]]||'''S'''
|-
| ||[[N. meningitidis]]||X1
|-
| ||[[Moraxella catarrhalis]]||'''S'''
|-
| ||[[H. influenzae]]||'''S'''
|-
| ||[[E. coli]]||'''S'''
|-
| ||[[Klebsiella]] sp||'''S'''
|-
| ||E. coli/Klebsiella ESBL+||R
|-
| ||E coli/Klebsiella KPC+||R
|-
| ||[[Enterobacter]] sp, AmpC neg||R
|-
| ||[[Enterobacter]] sp, AmpC pos||R
|-
| ||[[Serratia]] sp||R
|-
| ||Serratia marcescens||X1
|-
| ||[[Salmonella]] sp||'''S'''
|-
| ||[[Shigella]] sp||'''S'''
|-
| ||[[Proteus mirabilis]]||'''S'''
|-
| ||[[Proteus vulgaris]]||I
|-
| ||[[Providencia sp.]]||X1
|-
| ||[[Morganella sp.]]||R
|-
| ||[[Citrobacter freundii]]||R
|-
| ||[[Citrobacter diversus]]||X1
|-
| ||[[Citrobacter sp.]]||'''S'''
|-
| ||[[Aeromonas sp]]||X1
|-
| ||[[Acinetobacter sp.]]||X1
|-
| ||[[Pseudomonas aeruginosa]]||R
|-
| ||[[Burkholderia cepacia]]||X1
|-
| ||[[Stenotrophomonas maltophilia]]||X1
|-
| ||[[Yersinia enterocolitica]]||X1
|-
| ||[[Francisella tularensis]]||X1
|-
| ||[[Brucella sp.]]||X1
|-
| ||[[Legionella sp.]]||R
|-
| ||[[Pasteurella multocida]]||'''S'''
|-
| ||[[Haemophilus ducreyi]]||X1
|-
| ||[[Vibrio vulnificus]]||X1
|-
| Misc||[[Chlamydophila sp]]||X1
|-
| ||[[Mycoplasm pneumoniae]]||X1
|-
| ||[[Rickettsia sp]]||X1
|-
| ||[[Mycobacterium avium]]||X1
|-
| Anaerobes||[[Actinomyces]]||X1
|-
| ||[[Bacteroides fragilis]]||X1
|-
| ||[[Prevotella melaninogenica]]||X1
|-
| ||[[Clostridium difficile]]||X1
|-
| ||[[Clostridium (not difficile)]]||X1
|-
| ||[[Fusobacterium necrophorum]]||X1
|-
| ||[[Peptostreptococcus sp.]]||X1
|}
 
===Key===
{{Template:Antibacterial Spectra Key}}


==See Also==
==See Also==
*[[Antibiotics (Main)]]


==Source==
==References==
<references/>


<references/>
[[Category:Pharmacology]] [[Category:ID]]

Latest revision as of 16:12, 18 July 2025

General

  • Type: 3rd generation cephalosporin
  • Dosage Forms: capsule, oral suspension
  • Dosage Strengths: capsule: 300mg; oral suspension: 125mg/5mL, 250mg/5mL
  • Routes of Administration: PO
  • Common Trade Names: Omnicef

Adult Dosing

Pediatric Dosing

  • 14mg/kg/d PO divided q12-24hrs x10 days, max of 600mg/day

Special Populations

  • Pregnancy Rating: B
  • Lactation: Probably safe
  • Renal Dosing
    • Adult: CrCl <30, 300mg q24hrs; CrCl <10, 300mg q48hrs; supplement after HD
    • Pediatric: CrCl <30, 7mg/kg q24, max 300mg/dose; supplement after HD
  • Hepatic dosing not defined

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

  • Diarrhea
  • Bloody stools which are guiac negative and returns to normal color after cessation[1]

Pharmacology

  • Half-life: 100 min
  • Metabolism: Not appreciably metabolized
  • Excretion: Urine (7-25% as unchanged drug)
  • Mechanism of Action: Bactericidal, inhibits bacterial cell wall synthesis

Antibiotic Sensitivities[2]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep S
Strep. anginosus gp X1
Enterococcus faecalis R
Enterococcus faecium X1
MSSA S
MRSA R
CA-MRSA R
Staph. Epidermidis I
C. jeikeium X1
L. monocytogenes R
Gram Negatives N. gonorrhoeae S
N. meningitidis X1
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg R
Enterobacter sp, AmpC pos R
Serratia sp R
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris I
Providencia sp. X1
Morganella sp. R
Citrobacter freundii R
Citrobacter diversus X1
Citrobacter sp. S
Aeromonas sp X1
Acinetobacter sp. X1
Pseudomonas aeruginosa R
Burkholderia cepacia X1
Stenotrophomonas maltophilia X1
Yersinia enterocolitica X1
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida S
Haemophilus ducreyi X1
Vibrio vulnificus X1
Misc Chlamydophila sp X1
Mycoplasm pneumoniae X1
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces X1
Bacteroides fragilis X1
Prevotella melaninogenica X1
Clostridium difficile X1
Clostridium (not difficile) X1
Fusobacterium necrophorum X1
Peptostreptococcus sp. X1

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. ↑ Graves R, Weaver SP. Cefdinir-associated "bloody stools" in an infant. J Am Board Fam Med. 2008;21(3):246-248. doi:10.3122/jabfm.2008.03.070242
  2. ↑ Sanford Guide to Antimicrobial Therapy 2014
Retrieved from "https://www.wikem.org/w/index.php?title=Cefdinir&oldid=377050"